Therefore, targeted inhibition of site-specific P-gp is a promising strategy to improve the absorption for orally administered drugs, enhance the BBB penetrance of central nervous system (CNS) therapeutics, and reverse the MDR in cancer (Szakacs et al., 2006; Giacomini et al., 2010). The gene discussed is PGP; the disease is cancer.